Allergy · 2026
Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta-Analysis.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Yang, Li Ya-Chun, Li Sheng-Jie, Xu Meng, Hu Jia-Qian, Tian Wen-Qu, Chen Shi-Wei, Li Xue-Hui, He Ying, Lu Gan, Akdis Mübeccel, Agache Ioana, Akdis Cezmi A, Gao Ya-Dong
Аннотация
BACKGROUND: This systematic review (SR) aims to delineate the patterns and rationales for biologic switching in patients with severe asthma and evaluate its efficacy across the clinical remission criteria.
METHODS: The SR followed the PRISMA guidelines (PROSPERO CRD420251155819), with searches up to September 2025. Studies reporting on switching of biologics, including anti-IgE, anti-IL-4R/13R, anti-IL5/5R, and anti-TSLP, were included. Standardized mean difference (SMD) or mean difference (MD), and pooled relative risk (RR) were calculated for pre- and post- switch comparisons.
RESULTS: The SR included 49 studies (2292 switched severe asthma patients). The most common switching patterns were mepolizumab-benralizumab (n = 637) and omalizumab-mepolizumab/benralizumab (n = 386 or 305, respectively). Additional switching patterns included transitions from other biologicals to dupilumab or tezepelumab. Suboptimal asthma control (n = 1005, 77.0%) was the predominant reason for switching. The switch led to a significant reduction in exacerbations (SMD -1.03, 95% CI: -1.26 to -0.80, I2 = 89%), emergency department visits, hospitalizations, and maintenance oral corticosteroid dose and to improved asthma control ACT MD 5.18 (95% CI 4.32 to 6.04, I2 = 80%), ACQ MD -1.05 (95% CI -1.26 to -0.83, I2 = 45%) and lung function FEV1 MD 0.18 L (95% CI: 0.11 to 0.25, I2 = 0%). T2-biomarkers (blood eosinophils, total serum IgE, FeNO) significantly decreased.
CONCLUSION: Biologics switching represents a promising strategy supported by high-quality evidence of its clinical efficacy. Switching should consider clinical remission goals, co-morbidities, side effects, costs and reimbursement policies, and patient preferences.
METHODS: The SR followed the PRISMA guidelines (PROSPERO CRD420251155819), with searches up to September 2025. Studies reporting on switching of biologics, including anti-IgE, anti-IL-4R/13R, anti-IL5/5R, and anti-TSLP, were included. Standardized mean difference (SMD) or mean difference (MD), and pooled relative risk (RR) were calculated for pre- and post- switch comparisons.
RESULTS: The SR included 49 studies (2292 switched severe asthma patients). The most common switching patterns were mepolizumab-benralizumab (n = 637) and omalizumab-mepolizumab/benralizumab (n = 386 or 305, respectively). Additional switching patterns included transitions from other biologicals to dupilumab or tezepelumab. Suboptimal asthma control (n = 1005, 77.0%) was the predominant reason for switching. The switch led to a significant reduction in exacerbations (SMD -1.03, 95% CI: -1.26 to -0.80, I2 = 89%), emergency department visits, hospitalizations, and maintenance oral corticosteroid dose and to improved asthma control ACT MD 5.18 (95% CI 4.32 to 6.04, I2 = 80%), ACQ MD -1.05 (95% CI -1.26 to -0.83, I2 = 45%) and lung function FEV1 MD 0.18 L (95% CI: 0.11 to 0.25, I2 = 0%). T2-biomarkers (blood eosinophils, total serum IgE, FeNO) significantly decreased.
CONCLUSION: Biologics switching represents a promising strategy supported by high-quality evidence of its clinical efficacy. Switching should consider clinical remission goals, co-morbidities, side effects, costs and reimbursement policies, and patient preferences.